Live Quote · NASDAQIBRXHealthcare· Biotechnology

ImmunityBio, Inc.

$9.44 2.61%(+$0.24)
TickerSpark Score
75/100
Solid
47
Valuation
60
Profitability
100
Growth
68
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBRX research report →

52-Week Range71% of range
Low
$1.95
Current
$9.44
High
$12.43
Company Overviewimmunitybio.com

About the company

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases.

CEO
Richard Gerald Adcock
IPO
2015
Employees
671
HQ
San Diego, CA, US

Price Chart

+257.58% · this period
$11.55$6.77$1.98Jul 02Dec 31Jul 02
Valuation
Market Cap
$9.89B
P/E
-11.06
P/S
70.13
P/B
-11.14
EV/EBITDA
-14.88
Div Yield
0.00%
Profitability
Gross Margin
93.79%
Op Margin
-185.41%
Net Margin
-606.15%
ROE
138.69%
ROIC
-44.51%
Growth & Income
Revenue
$113.29M · 668.31%
Net Income
$-351,398,000 · 15.03%
EPS
$-0.38 · 35.59%
Op Income
$-256,027,000
FCF YoY
22.44%
Performance & Tape
52W High
$12.43
52W Low
$1.95
50D MA
$7.68
200D MA
$5.40
Beta
0.10
Avg Volume
13.97M

Get TickerSpark's AI analysis on IBRX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 29, 26Selecky Christobelother30,000
Jun 29, 26Selecky Christobelother33,549
Jun 30, 26Selecky Christobelother300
Jun 29, 26Selecky Christobelother30,000
Jun 29, 26Selecky Christobelother33,549
Jun 29, 26Selecky Christobelother32,173
Jun 30, 26Selecky Christobelother700
Jun 29, 26Selecky Christobelother32,173
Jun 30, 26Selecky Christobelother300
Jun 30, 26Selecky Christobelother700
Coverage · IBRX

Our IBRX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on IBRX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate IBRX report →
Internal Compare

Similar companies

Peers in the same neighborhood.